FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-028					
Estimated average burden						

0.5

hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
Name and Address of Reporting Person* Longcor Jarrod				2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]						5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 01/25/2022							X Officer (give title below) Other (specify below) Chief Business Officer					
(Street) FLORHAM, NJ 07932											6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqui						ies Acquire	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			Execution Date, if Code (A) or Dis			Securities Accal or Disposed nstr. 3, 4 and 5	of (D) Ov Tr	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) Covership of Indirect Form: Direct (D) or Indirect (I) (Instr. 4)								
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if				5. Number of (1) Derivative I Securities Acquired (A) or Disposed of (D)		Expiration Date of Und (Month/Day/Year) Securit		required to B control eficially Ov rities)	o respond unumber. wned ad Amount ying	inless the	9. Number of Derivative Securities Beneficially Owned Following	of 10. Ownersh Form of Derivati Security Direct (I	Benefici Ownersh (Instr. 4)
					Code	v	(Instr. 3, 4 and 5)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction (Instr. 4)	or Indire (I) (Instr. 4)	
Stock option (right to buy)	\$ 0.55	01/25/2022			A		475,000		(1)	01/25/2032	Commo		\$ 0	475,000) D	
Repor	ting O	wners														
Reporting Owner Name / Address Director						Relationsh	nips									
			10% Owner Officer					Other								

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Longcor Jarrod C/O CELLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE FLORHAM, NJ 07932			Chief Business Officer			

Signatures

/s/ Christina Blakley, attorney-in-fact for Jarrod Longcor	01/27/2022
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.

Potential persons who are to respond to the collection of information contained in this form are no	ot required to respond unless the form displays a currently valid OMB number.